You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News and reporting on ovarian cancer.
Aspira said it will bring its experience in patient sample recruitment and ovarian cancer assay development to the collaboration.
The company also announced John Leite, the former leader of clinical business development activities at Illumina, had joined the firm as chief business officer.
A deal with Burning Rock will allow the test to be used in trials and clinics in China, and Myriad will license its technology to French and German pathology labs.
FoundationOne Liquid CDx can now be used as a companion diagnostic for therapies to treat advanced ovarian, breast, and non-small cell lung cancer.
The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
The targeted sequencing assay analyzes 12 genes and can be paired with the firm's BRCA gene testing kit.
An analysis of societal and health system cost-effectiveness and outcomes points to the benefits of expanding pathogenic BRCA1/2 variant testing in six countries.
In a proof-of-concept study, the group has demonstrated its platform could detect a biomarker of breast tumor metastasis and other disease biomarkers.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The agency reviewed data showing that HRD-positive patients on the olaparib/bevacizumab combination had median progression-free survival of 37.2 months.